Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Shahneen Sandhu(The University of Melbourne), Thomas Müller(490 BioTech (United States)), Sarah M. McWhirter(490 BioTech (United States)), Omid Hamid(Cedars-Sinai Medical Center), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Toshio Shimizu(Wakayama Medical University), Neeltje Steeghs(Peter MacCallum Cancer Centre), Lisa Kattenhorn(American Institutes for Research), Nitya Nair(490 BioTech (United States)), Agostina Stradella(Institut Català d'Oncologia), Jason J. Luke(University of Chicago), Georgina V. Long(The University of Sydney), Randy F. Sweis(University of Illinois Chicago), Marc R. Pelletier(American Institutes for Research), Andrew Bean(Tris Pharma (United States)), Nancy Lewis(Tris Pharma (United States)), Anna Spreafico(University Health Network), Stefan Kasper(Essen University Hospital), Reinhard Dummer(University Hospital of Zurich), Xinhui Chen(Novartis (Switzerland))
Cited by 226
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k